Trevena Inc (NASDAQ:TRVN)‘s stock had its “buy” rating reiterated by stock analysts at Cowen and Company in a research note issued on Wednesday. They currently have a $13.00 price objective on the biopharmaceutical company’s stock. Cowen and Company’s price objective indicates a potential upside of 283.48% from the company’s previous close. The analysts wrote, “TRVN […]
